JPMorgan Chase & Co. Issues Positive Forecast for Humana (NYSE:HUM) Stock Price

Key Points

• JPMorgan raised its Humana price target to $393 from $316 while maintaining a neutral rating, implying roughly 1.74% upside from the previous close.
• Analyst sentiment is broadly positive, with Humana carrying a “Moderate Buy” consensus rating and an average price target of $395.22; recent targets range as high as $480.
• Humana exceeded quarterly expectations, reporting $7.61 in EPS versus a $7.27 estimate and $40.89 billion in revenue, up 26.2% year over year.

Humana (NYSE:HUM - Get Free Report) had its target price lifted by analysts at JPMorgan Chase & Co. from $316.00 to $393.00 in a report issued on Monday,Benzinga reports. The firm currently has a "neutral" rating on the insurance provider's stock. JPMorgan Chase & Co.'s price objective indicates a potential upside of 1.74% from the stock's previous close.

HUM has been the subject of several other reports. UBS Group began coverage on Humana in a research report on Thursday, July 30th. They set a "buy" rating for the company. Guggenheim raised their price objective on Humana from $269.00 to $471.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Truist Financial lifted their target price on Humana from $320.00 to $415.00 and gave the stock a "hold" rating in a report on Tuesday, July 14th. Evercore raised shares of Humana from an "in-line" rating to an "outperform" rating and set a $480.00 price target on the stock in a research note on Wednesday, July 29th. Finally, Seaport Research Partners cut shares of Humana to a "neutral" rating in a report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $395.22.

Humana Price Performance

Shares of HUM traded up $1.29 during mid-day trading on Monday, hitting $386.29. 805,688 shares of the company traded hands, compared to its average volume of 1,797,993. The stock has a market capitalization of $46.39 billion, a price-to-earnings ratio of 36.60, a PEG ratio of 2.20 and a beta of 0.72. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average of $377.18 and a 200 day moving average of $271.64. Humana has a one year low of $163.11 and a one year high of $428.88.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The business had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. During the same quarter in the prior year, the firm posted $6.27 earnings per share. The firm's revenue for the quarter was up 26.2% compared to the same quarter last year. As a group, equities analysts expect that Humana will post 9.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humana

Several large investors have recently modified their holdings of the stock. Revolve Wealth Partners LLC acquired a new stake in Humana during the 4th quarter worth approximately $202,000. Woodline Partners LP raised its holdings in Humana by 460.0% in the 1st quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider's stock valued at $2,697,000 after acquiring an additional 8,372 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Humana by 53.7% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider's stock valued at $316,000 after buying an additional 452 shares in the last quarter. Cresset Asset Management LLC increased its stake in shares of Humana by 10.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider's stock valued at $581,000 after purchasing an additional 222 shares during the last quarter. Finally, WINTON GROUP Ltd grew its holdings in shares of Humana by 58.5% during the 2nd quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider's stock valued at $582,000 after purchasing an additional 879 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source